Jenkoo (@Jenkoool) profile picture

AIM Investor

Joined February 2022
Replying to @AndrewDigby3
Relax Capt 😊 We got the major news (early) that we wanted. PK & PD is seemingly working as expected. Therefore Exatecan will 90+% chance do the same. Don’t worry about the SP or the raise. Neither matter too much vs the bigger picture. Enjoy the weekend mate
1
10
218
I’m trying not to get too excited about 6103 and the big reveal….. but I’m finding it difficult…. The breadcrumbs are more like ‘full on slices’ right now… and we’re following them all the way to the bakery 🍞 #avct
5
3
52
3,111
“This promises to be a transformative period for Avacta and our patients” I’m getting a sense of confidence…. You don’t use words like ‘promises’ if the data is iffy & partners are disengaged. #avct
4
44
2,047
A nice little reminder of what we hold from our very own CC 🫶🏻 #avct
2
11
68
4,953
I think we can finally say the sp has turned a corner. The coming days ‘could’ be the last we see of <100p for the rest of time. Vindication for our long term commitment is underway. ☀️ 🫶🏻🥇 #avct
6
5
1
90
9,619
There are people out there that sold #avct shares at 71p this morning convinced it would drop further….
3
4
62
4,149
Today’s RNS is further proof that the disconnect is real. It simply can not continue like this. Investors know it & will certainly will be rewarded. The game of chess is well underway, with CC lining up her chess pieces ahead of calling checkmate on BP #avct
2
3
52
2,171
I think this has largely been missed by investors so worth highlighting because if you understand the below illustrations, you’ll realise that the 6103 trial has another hugely significant differential from the 6k trial (which feels like its been running since 1987) 😉 1/3 #avct
2
4
36
2,061
Absolutely love this graph & the screenshot of the 3 main benefits vs what is close to a $5 billion per annum drug. #avct The data is consistently showing 6103 outperforms. I can’t believe the market has not twigged yet. The disconnect is crazy…. For now 🫶🏻🥇
2
7
69
3,881
For those new to #avct drawn in by the incredible data being shared. Here’s your quick look at the platform, benefits and investment potential. Full disclosure- made by AI. 🤖
1
6
1
55
4,468
#avct Funding now into Q1/27…. With 6103 P1a initial results late 26….. Anyone find that remotely linked? Yeh me too. In summary I suspect: Q3 for a Faridox deal inc BTD which will drive value & fund P2 Q1 BP dog fight for 6103… potentially resulting in an all out TO
1
17
1,259
Mixed thoughts on #avct RNS. Mainly positive. I hoped for closer to 70p however either way it’s not a huge raise. I must admit I did like this section which pretty much confirms the 6k trials are deal worthy We’ve asked for a while, how do you price it? Maybe H2 we get answers
3
1
31
2,094
My favourite slide in the deck…. AND my 2 favourite snippets from the ‘must hear’ presentation #avct Superb
2
15
84
4,118
#avct 6103 likely gets another one over ADC rivals Extended shelf life @ higher temps (fridge not freezer) Easier reconstitution at clinic (add diluent before IV administration) Standard refrigerated logistics, lower risk of excursions, & reduced distribution costs/complexity
3
51
3,036
Rumours have it that Francis has been visiting local bars in nothing but a robe and slippers… 😉 #avct
2
1
16
1,832
Still buzzing about the removal of Max Dosing Limit for Faridox. CC is 🥇 Does her master plan include for increasing patient numbers in P1b to drive up odds of achieving breakthrough therapy status for 6k pre-P2? This being the milestone for a huge uplift in deal value…..#avct
1
1
44
2,727
6103 IND APPROVED 🫶🏻 #AVCT
Avacta is pleased to announce U.S. FDA clearance of the IND application for the Company’s second program FAP-Exd (AVA6103), the first pre|CISION peptide drug conjugate based on the highly potent topoisomerase I inhibitor, exatecan. avacta.com/avacta-announces-… #AVCT
1
1
43
1,622